<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Extracorporeal life support in adults: Extracorporeal carbon dioxide removal (ECCO2R)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Extracorporeal life support in adults: Extracorporeal carbon dioxide removal (ECCO2R)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Extracorporeal life support in adults: Extracorporeal carbon dioxide removal (ECCO2R)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Darryl Abrams, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cara Agerstrand, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Justin Fried, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel Brodie, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott Manaker, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3991420596">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extracorporeal carbon dioxide removal (ECCO
         <sub>
          2
         </sub>
         R) is an advanced form of life support that is mostly used in patients with severe hypercapnic respiratory failure without hypoxemia.
        </p>
        <p>
         This topic will provide an overview of implementation and management of patients receiving ECCO
         <sub>
          2
         </sub>
         R. Other extracorporeal life support-relevant topics are found elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/134279.html" rel="external">
          "Extracorporeal life support in adults: Management of venoarterial extracorporeal membrane oxygenation (V-A ECMO)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/127765.html" rel="external">
          "COVID-19: Extracorporeal membrane oxygenation (ECMO)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/131002.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: The role of transesophageal echocardiography (TEE)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1600221106">
         <span class="h1">
          TERMINOLOGY AND PHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         ECCO
         <sub>
          2
         </sub>
         R is a form of extracorporeal life support (ECLS) that is mostly used clinically for temporary support of patients with acute or acute on chronic hypercapnic respiratory failure. Additional terms are described in the table  (
         <a class="graphic graphic_table graphicRef140283" href="/z/d/graphic/140283.html" rel="external">
          table 1
         </a>
         ). Details of ECCO
         <sub>
          2
         </sub>
         R and other forms of ECLS are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview", section on 'Terminology'
         </a>
         .)
        </p>
        <p>
         The configuration of the circuit in ECCO
         <sub>
          2
         </sub>
         R is comprised of a drainage cannula that removes blood, typically from a large central or peripheral vein. Blood is pumped into a membrane lung where CO
         <sub>
          2
         </sub>
         is removed via the extracorporeal circuit, after which, the blood is reinfused back into the systemic circulation (typically the same or a different vein). Common configurations are discussed below. (See
         <a class="local">
          'Configurations'
         </a>
         below.)
        </p>
        <p>
         ECCO
         <sub>
          2
         </sub>
         R is defined physiologically by the intention to primarily remove CO
         <sub>
          2
         </sub>
         in a given patient. As such, if the intention is to remove CO
         <sub>
          2
         </sub>
         without the substantial provision of extracorporeal oxygenation, then the application of ECLS is termed ECCO
         <sub>
          2
         </sub>
         R. If oxygenation (in addition to CO
         <sub>
          2
         </sub>
         removal) is the goal of therapy, then the application is extracorporeal membrane oxygenation (ECMO). ECCO
         <sub>
          2
         </sub>
         R may be applied at lower blood flow rates on average (typically &lt;2 L/minute) than ECMO and contributes minimally to oxygenation; whereas ECMO, which is delivered at higher blood flow rates (eg, 3 to 7 L/minute), accomplishes both oxygenation and CO
         <sub>
          2
         </sub>
         removal. Further details regarding the determinants of gas exchange are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview", section on 'Determinants of gas exchange'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1937790445">
         <span class="h1">
          CLINICAL APPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to selecting patients for venovenous (V-V) extracorporeal membrane oxygenation (ECMO) is discussed in this section. Guidelines that describe the indications and practice of ECLS/ECMO are published by the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.elso.org%2F&amp;token=NyRkA1K%2BEfcjom0B%2BqrukvFcezSIP8grIF6J6FVMBCQ%3D&amp;TOPIC_ID=134496" target="_blank">
          Extracorporeal Life Support Organization
         </a>
         (ELSO) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4056175415">
         <span class="h2">
          Status asthmaticus
         </span>
         <span class="headingEndMark">
          —
         </span>
         This is the most common application of ECCO
         <sub>
          2
         </sub>
         R. ECCO
         <sub>
          2
         </sub>
         R is appropriate in patients with status asthmaticus and acceptable oxygenation who have severe, uncompensated respiratory acidosis (eg, pH &lt;7.2) or evidence of excess dynamic hyperinflation and intrinsic positive end-expiratory pressure (PEEPi; this includes the presence of barotrauma, such as pneumothorax and pneumomediastinum) despite optimization of medical therapy, invasive mechanical ventilation, and use of sedation with neuromuscular blockade [
         <a href="#rid3">
          3
         </a>
         ]. Conventional management of asthma exacerbations is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">
          "Acute exacerbations of asthma in adults: Emergency department and inpatient management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/570.html" rel="external">
          "Invasive mechanical ventilation in adults with acute exacerbations of asthma"
         </a>
         .)
        </p>
        <p>
         Oxygenation is classically preserved in this population such that ECMO is uncommonly needed. However, for those in whom oxygenation is inadequate, V-V ECMO is more appropriate than ECCO
         <sub>
          2
         </sub>
         R. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)"
         </a>
         .)
        </p>
        <p>
         Data to support ECCO
         <sub>
          2
         </sub>
         R use in this population are limited to case series that suggest it may be successful as a temporizing measure until the asthma exacerbation resolves [
         <a href="#rid4">
          4-9
         </a>
         ]. As an example, in a series of 26 adults with status asthmaticus, ECCO
         <sub>
          2
         </sub>
         R resulted in improved gas exchange, peak airway pressures, and PEEPi, with a high rate of extubation during ECCO
         <sub>
          2
         </sub>
         R support (77 percent). All patients survived to discharge. Complications included cannula-associated deep venous thrombosis (23 percent) and bleeding requiring transfusions (15 percent).
        </p>
        <p class="headingAnchor" id="H3145688666">
         <span class="h2">
          End-stage lung disease with ECCO2R as a bridge to lung transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         While many patients with severe end-stage lung disease need V-V ECMO to provide both oxygenation and CO
         <sub>
          2
         </sub>
         removal as a bridge to lung transplantation (BTT), a small proportion need only CO
         <sub>
          2
         </sub>
         removal for acute on chronic hypercapnic respiratory failure and are therefore candidates for ECCO
         <sub>
          2
         </sub>
         R. ECCO
         <sub>
          2
         </sub>
         R under these circumstances can provide temporary support and facilitate patient participation in physical therapy in preparation for transplant. Additional details including timing of ECCO
         <sub>
          2
         </sub>
         R and data to support ECLS as a BTT are described separately. (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview", section on 'ECLS as a bridge to an endpoint'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Severe lung disease with ECMO as a bridge to lung transplantation'
         </a>
         .)
        </p>
        <p>
         General criteria for lung transplant are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">
          "Lung transplantation: An overview", section on 'Referral for transplant evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">
          "Lung transplantation: Disease-based choice of procedure", section on 'Disease-based considerations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3142455981">
         <span class="h2">
          Investigational considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         ECCO
         <sub>
          2
         </sub>
         R has also been the target of several proposed investigational uses:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) as a means to facilitate early extubation or
         </strong>
         <strong>
          avoid mechanical ventilation
         </strong>
         – In patients with AECOPD, ECCO
         <sub>
          2
         </sub>
         R, as a means to facilitate early removal of invasive mechanical ventilation or avoid intubation altogether, has been demonstrated to be safe and feasible in nonrandomized studies and is the subject of both ongoing and planned randomized controlled trials [
         <a href="#rid10">
          10-14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate to severe acute respiratory distress syndrome (ARDS)
         </strong>
         – ECCO
         <sub>
          2
         </sub>
         R is also being investigated as a means of maintaining adequate pH and partial pressure of arterial CO
         <sub>
          2
         </sub>
         (PaCO
         <sub>
          2
         </sub>
         ) in ventilated patients with ARDS when the goal is to apply an ultra-lung-protective ventilation strategy but when ECMO support is not yet indicated [
         <a href="#rid15">
          15
         </a>
         ]. While pilot data have shown feasibility with such a strategy [
         <a href="#rid16">
          16-18
         </a>
         ], a large randomized trial failed to detect a mortality benefit when ECCO
         <sub>
          2
         </sub>
         R-facilitated ultra-lung-protective ventilation was compared with conventional management in patients with moderate to severe acute hypoxemic respiratory failure [
         <a href="#rid19">
          19
         </a>
         ]. This study is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">
          "Acute respiratory distress syndrome: Ventilator management strategies for adults", section on 'Ventilator strategies of questionable benefit or harm'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1646699747">
         <span class="h2">
          General evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         When evaluating patients who have a potential indication for ECCO
         <sub>
          2
         </sub>
         R, we assess candidacy clinically. This clinical evaluation is similar to that described for patients being assessed for V-V or venoarterial (V-A) ECMO. Details of this assessment are provided separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview", section on 'Patient-specific factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Initial clinical assessment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/134279.html" rel="external">
          "Extracorporeal life support in adults: Management of venoarterial extracorporeal membrane oxygenation (V-A ECMO)", section on 'Initial clinical assessment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Notably, in this population, we also assess the risk of concomitant severe hypoxemia. If patients are believed to be at considerable risk for progression to severe hypoxemia, we place cannulae that are large enough to accommodate both ECCO
         <sub>
          2
         </sub>
         R and ECMO, should ECMO be needed to provide substantial oxygenation support at some point. Once the decision is made to proceed, a plan is made for catheter insertion. (See
         <a class="local">
          'Configurations, catheterization, initiation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H428775949">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to ECCO
         <sub>
          2
         </sub>
         R are similar to those for ECMO and are listed on the table  (
         <a class="graphic graphic_table graphicRef140303" href="/z/d/graphic/140303.html" rel="external">
          table 2
         </a>
         ). Further details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Assess contraindications and technical challenges'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134279.html" rel="external">
          "Extracorporeal life support in adults: Management of venoarterial extracorporeal membrane oxygenation (V-A ECMO)", section on 'Contraindications (absolute and relative)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H51047833">
         <span class="h1">
          CONFIGURATIONS, CATHETERIZATION, INITIATION
         </span>
        </p>
        <p class="headingAnchor" id="H3883346578">
         <span class="h2">
          Configurations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common configuration used in ECCO
         <sub>
          2
         </sub>
         R is venovenous (V-V) ECCO
         <sub>
          2
         </sub>
         R. We use venous sites similar to those used in V-V extracorporeal membrane oxygenation (ECMO; eg, two-site approach with femoral venous drainage and internal jugular venous reinfusion  (
         <a class="graphic graphic_figure graphicRef140301" href="/z/d/graphic/140301.html" rel="external">
          figure 1
         </a>
         ) or a single-site, dual-lumen approach via an internal jugular venous access point  (
         <a class="graphic graphic_figure graphicRef140678" href="/z/d/graphic/140678.html" rel="external">
          figure 2
         </a>
         )). Rarely, we use a low-flow arteriovenous (A-V) approach to ECCO
         <sub>
          2
         </sub>
         R (eg, femoral artery as the drainage site and femoral vein as the reinfusion site). This approach relies on native cardiac output rather than an external pump to generate extracorporeal blood flow [
         <a href="#rid20">
          20
         </a>
         ]. Further details regarding V-V ECMO configurations are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Venovenous ECMO configurations and sites'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3776267760">
         <span class="h2">
          Catheter insertion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whereas oxygenation in ECMO is largely dependent on the circuit blood flow rate, CO
         <sub>
          2
         </sub>
         removal is primarily determined by the sweep gas flow rate, due to the efficiency with which CO
         <sub>
          2
         </sub>
         transfer occurs across the membrane. Therefore, ECCO
         <sub>
          2
         </sub>
         R can be achieved with lower blood flow rates and correspondingly smaller cannulae than what is usually required for oxygenation during ECMO (eg, 20 French drainage and 18 French reinfusion, or smaller). However, if there is an anticipated need for extracorporeal oxygenation, we place larger cannulae to support ECMO, should it be needed at some point during the course of the patient's illness. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Catheter insertion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2265022332">
         <span class="h2">
          Initial settings and titration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following cannulation, the patient is immediately connected to the ECCO
         <sub>
          2
         </sub>
         R circuit (typically the pump, membrane lung, and monitor) and sweep gas (a blend of oxygen and air, the fractions of which are determined by the provider and set through a blender) is connected to the membrane lung.
        </p>
        <p>
         There are no universally agreed upon initial settings. Typical settings are dictated by the degree of support that may be needed and the type of device used. Some devices are designed specifically for "low-flow" ECCO
         <sub>
          2
         </sub>
         R (eg, blood flow rates &lt;1 L/minute), whereas other circuits (especially with centrifugal pumps) are optimally designed for &gt;3 L/minute and may exhibit higher rates of hemolysis and other hematologic derangements at lower blood flow rates [
         <a href="#rid21">
          21-24
         </a>
         ]. As an estimate, we typically use the following, achieved incrementally over the first few minutes after initiation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pump speed to achieve an extracorporeal blood flow appropriate to the particular pump (eg, as low as 0.4 L/minute and as high as 3 L/minute or greater).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sweep gas flow that typically ranges from 1 to 10 L/minute.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fraction of delivered oxygen (FDO
         <sub>
          2
         </sub>
         ) is typically set to 1.0. However, when there is no intention to provide extracorporeal oxygenation, lower FDO
         <sub>
          2
         </sub>
         , or even air (ie, FDO
         <sub>
          2
         </sub>
         0.21), may be used with equally effective CO
         <sub>
          2
         </sub>
         removal.
        </p>
        <p>
        </p>
        <p>
         Immediately following initiation, sweep gas flow is titrated in a similar fashion to that described in V-V ECMO. For those with marked, uncompensated respiratory acidosis (eg, partial pressure of arterial CO
         <sub>
          2
         </sub>
         [PaCO
         <sub>
          2
         </sub>
         ] &gt;60 mmHg with corresponding acidemia), the sweep gas flow rate should be gradually increased over several hours to avoid complications potentially associated with rapid changes in PaCO
         <sub>
          2
         </sub>
         (eg, intracerebral hemorrhage) [
         <a href="#rid25">
          25
         </a>
         ]. Further details regarding titration are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Initial settings and titration'
         </a>
         .)
        </p>
        <p>
         Factors that determine CO
         <sub>
          2
         </sub>
         removal are shown in the table  (
         <a class="graphic graphic_table graphicRef140684" href="/z/d/graphic/140684.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1338121437">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
        </p>
        <p class="headingAnchor" id="H173618651">
         <span class="h2">
          Invasive mechanical ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For those receiving ECCO
         <sub>
          2
         </sub>
         R for severe asthma exacerbations or as bridge to transplantation, we try to wean patients off of invasive mechanical ventilation and endotracheally extubate them. We maintain pH and partial pressure of arterial CO
         <sub>
          2
         </sub>
         (PaCO
         <sub>
          2
         </sub>
         ) with the extracorporeal circuit and oxygenation with supplemental oxygen as needed. (See
         <a class="medical medical_review" href="/z/d/html/1650.html" rel="external">
          "Initial weaning strategy in mechanically ventilated adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">
          "Extubation management in the adult intensive care unit"
         </a>
         .)
        </p>
        <p>
         For those patients with evidence of airway obstruction (eg, severe asthma exacerbations or acute exacerbations of chronic obstructive pulmonary disease) who are unable to be endotracheally extubated, we favor a mechanical ventilation strategy that minimizes minute ventilation, with very low respiratory rates (eg, &lt;10) and tidal volumes, with prolongation of the expiratory time, so as to minimize gas trapping and intrinsic positive end-expiratory pressure. We favor prompt discontinuation of neuromuscular blocking agents once ECCO
         <sub>
          2
         </sub>
         R has been initiated (if in use prior to ECCO
         <sub>
          2
         </sub>
         R) and subsequent minimization of sedation, both of which will help facilitate early endotracheal extubation.
        </p>
        <p class="headingAnchor" id="H2352982814">
         <span class="h2">
          Others
         </span>
         <span class="headingEndMark">
          —
         </span>
         All other supportive care issues that pertain to patients in the intensive care unit receiving ECCO
         <sub>
          2
         </sub>
         R, including routine measures and circuit care, are similar to those in patients with venovenous (V-V) extracorporeal membrane oxygenation (ECMO), the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Supportive therapies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Daily assessment and circuit monitoring'
         </a>
         .)
        </p>
        <p>
         There is no consensus on anticoagulation targets for ECCO
         <sub>
          2
         </sub>
         R specifically. A reasonable initial target is similar to that for patients on V-V ECMO, but higher targets may be needed. Most experts agree that the lower the blood flow rate applied, the higher the anticoagulation goal should be to minimize the risk of thrombosis. The specific goals will also reflect the particular device used and any known proclivity of the patient for bleeding or clotting. Specific goals for anticoagulation in patients receiving V-V ECMO are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Anticoagulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3708896798">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The complications of ECCO
         <sub>
          2
         </sub>
         R are listed in the table  (
         <a class="graphic graphic_table graphicRef140676" href="/z/d/graphic/140676.html" rel="external">
          table 4
         </a>
         ) and are similar to that described for venovenous (V-V) extracorporeal membrane oxygenation (ECMO). Further details regarding the complications of V-V ECMO are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1186708318">
         <span class="h1">
          DEVELOPMENT OF HYPOXEMIC RESPIRATORY FAILURE OR CARDIAC FAILURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients receiving ECCO
         <sub>
          2
         </sub>
         R who develop hypoxemic respiratory failure or cardiac failure should be managed medically. Should such therapies fail, our threshold to convert to venovenous or venoarterial extracorporeal membrane oxygenation is low, assuming escalation is both clinically appropriate and concordant with the patient's goals of care. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134279.html" rel="external">
          "Extracorporeal life support in adults: Management of venoarterial extracorporeal membrane oxygenation (V-A ECMO)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3484942329">
         <span class="h1">
          WEANING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the underlying disease process has sufficiently improved, we wean ECCO
         <sub>
          2
         </sub>
         R. This process is similar to that in venovenous extracorporeal membrane oxygenation with the focus being on maintaining ventilation rather than oxygenation. These details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Weaning'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2144619567">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – Extracorporeal carbon dioxide removal (ECCO
         <sub>
          2
         </sub>
         R) is a form of extracorporeal life support. ECCO
         <sub>
          2
         </sub>
         R is mostly used for temporary support of patients with acute or acute on chronic hypercapnic respiratory failure  (
         <a class="graphic graphic_table graphicRef140283" href="/z/d/graphic/140283.html" rel="external">
          table 1
         </a>
         ). The configuration of the circuit in ECCO
         <sub>
          2
         </sub>
         R is comprised of a drainage cannula that removes blood, typically from a large central or peripheral vein. CO
         <sub>
          2
         </sub>
         is removed extracorporeally and the blood is reinfused back into the systemic circulation (typically the same or a different vein). (See
         <a class="local">
          'Terminology and physiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – Suitable candidates for ECCO
         <sub>
          2
         </sub>
         R are the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with status asthmaticus and acceptable oxygenation who have severe, uncompensated respiratory acidosis (eg, pH &lt;7.2) or evidence of excess dynamic hyperinflation and intrinsic positive end-expiratory pressure (this includes the presence of barotrauma, such as pneumothorax and pneumomediastinum) despite optimization of medical therapy, invasive mechanical ventilation, and use of sedation with neuromuscular blockade. (See
         <a class="local">
          'Status asthmaticus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with acute on chronic hypercapnic respiratory failure due to end-stage lung disease who are candidates for lung transplantation. (See
         <a class="local">
          'End-stage lung disease with ECCO2R as a bridge to lung transplantation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Severe lung disease with ECMO as a bridge to lung transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Contraindications to ECCO
         <sub>
          2
         </sub>
         R are similar to those for venovenous (V-V) extracorporeal membrane oxygenation (ECMO) and are listed on the table  (
         <a class="graphic graphic_table graphicRef140303" href="/z/d/graphic/140303.html" rel="external">
          table 2
         </a>
         ). These contraindications are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Assess contraindications and technical challenges'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedural issues and initiation
         </strong>
         – The most common configuration used is V-V ECCO
         <sub>
          2
         </sub>
         R. Catheter insertion is similar to that in V-V ECMO, but smaller cannulae may be used (eg, 20 French drainage and 18 French reinfusion, or smaller) when there is no anticipated expectation of needing ECMO for oxygenation support at some point during the patient's illness. (See
         <a class="local">
          'Configurations, catheterization, initiation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Catheter insertion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following cannulation, the patient is immediately connected to the ECCO
         <sub>
          2
         </sub>
         R circuit. Although variable, typical initial settings are the following (see
         <a class="local">
          'Initial settings and titration'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pump speed to achieve an extracorporeal blood flow appropriate to the particular pump (eg, 0.4 L/minute to 3 L/minute or greater).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sweep gas flow that typically ranges from 1 to 10 L/minute.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fraction of delivered oxygen (FDO
         <sub>
          2
         </sub>
         ) is typically set to 1.0, although lower FDO
         <sub>
          2
         </sub>
         , or even air (ie, FDO
         <sub>
          2
         </sub>
         0.21) may be used with equally effective CO
         <sub>
          2
         </sub>
         removal when clinically appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Immediately following initiation, sweep gas flow is titrated slowly in order to lower the partial pressure of arterial CO
         <sub>
          2
         </sub>
         (PaCO
         <sub>
          2
         </sub>
         ) and increase the pH in a similar fashion to that described in V-V ECMO. (See
         <a class="local">
          'Initial settings and titration'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Initial settings and titration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care and daily assessment
         </strong>
         – Supportive care and daily assessment are similar to that in V-V ECMO with the following exceptions (see
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Supportive therapies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Daily assessment and circuit monitoring'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mechanical ventilation
         </strong>
         – Mechanical ventilation is typically weaned with the goal of endotracheal extubation (eg, 24 to 48 hours) while managing PaCO
         <sub>
          2
         </sub>
         and pH with the extracorporeal circuit and oxygenation with the provision of supplemental oxygen as needed. (See
         <a class="medical medical_review" href="/z/d/html/1650.html" rel="external">
          "Initial weaning strategy in mechanically ventilated adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">
          "Extubation management in the adult intensive care unit"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anticoagulation
         </strong>
         – All patients require anticoagulation due to the high risk of thrombosis. A reasonable initial target is similar to that for patients on V-V ECMO. However, in some cases, higher targets are needed. While there is no consensus on anticoagulation targets for ECCO
         <sub>
          2
         </sub>
         R specifically, most experts agree that the lower the blood flow rate applied, the higher the anticoagulation goal should be to minimize the risk of thrombosis. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Anticoagulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – The complications of ECCO
         <sub>
          2
         </sub>
         R are listed in the table  (
         <a class="graphic graphic_table graphicRef140676" href="/z/d/graphic/140676.html" rel="external">
          table 4
         </a>
         ) and similar to that described for V-V ECMO, the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Weaning
         </strong>
         – Once the underlying disease process has sufficiently improved, we wean ECCO
         <sub>
          2
         </sub>
         R. This process is similar to that in V-V ECMO with the focus on ventilation rather than both ventilation and oxygenation. These details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">
          "Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Weaning'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          https://www.elso.org/Portals/0/ELSO%20Guidelines%20General%20All%20ECLS%20Version%201_4.pdf (Accessed on July 23, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai HC, Chang CH, Tsai FC, et al. Acute Respiratory Distress Syndrome With and Without Extracorporeal Membrane Oxygenation: A Score Matched Study. Ann Thorac Surg 2015; 100:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bromberger BJ, Agerstrand C, Abrams D, et al. Extracorporeal Carbon Dioxide Removal in the Treatment of Status Asthmaticus. Crit Care Med 2020; 48:e1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro MB, Kleaveland AC, Bartlett RH. Extracorporeal life support for status asthmaticus. Chest 1993; 103:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kukita I, Okamoto K, Sato T, et al. Emergency extracorporeal life support for patients with near-fatal status asthmaticus. Am J Emerg Med 1997; 15:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikkelsen ME, Woo YJ, Sager JS, et al. Outcomes using extracorporeal life support for adult respiratory failure due to status asthmaticus. ASAIO J 2009; 55:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinack C, Lenherr R, Hendra H, Franzen D. The use of life-saving extracorporeal membrane oxygenation (ECMO) for pregnant woman with status asthmaticus. J Asthma 2017; 54:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maqsood U, Patel N. Extracorporeal membrane oxygenation (ECMO) for near-fatal asthma refractory to conventional ventilation. BMJ Case Rep 2018; 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Lascio G, Prifti E, Messai E, et al. Extracorporeal membrane oxygenation support for life-threatening acute severe status asthmaticus. Perfusion 2017; 32:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrams DC, Brenner K, Burkart KM, et al. Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013; 10:307.
          </a>
         </li>
         <li class="breakAll">
          Del Sorbo L, Pisani L, Filippini C, et al. Extracorporeal CO2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med 2014; 43:120.
         </li>
         <li class="breakAll">
          Alung Technologies. Extracorporeal CO2 Removal with the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD (VENT-AVOID). Available at: http://clinicaltrials.gov/ct2/show/NCT03255057 (Accessed on August 26, 2017).
         </li>
         <li class="breakAll">
          Xenios AG. Early Extubation by ECCO2R Compared to IMV in Patients with Severe Acute Exacerbation of COPD (X-COPD). Available at: http://clinicaltrials.gov/ct2/show/NCT03584295 (Accessed on June 18, 2021).
         </li>
         <li class="breakAll">
          University of Bologna. Extracorporeal CO2 Removal for Acute Decompensation of COPD (ORION). Available at: http://clinicaltrials.gov/ct2/show/NCT04582799 (Accessed on June 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodie D, Slutsky AS, Combes A. Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review. JAMA 2019; 322:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Combes A, Fanelli V, Pham T, et al. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med 2019; 45:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med 2013; 39:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terragni PP, Del Sorbo L, Mascia L, et al. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology 2009; 111:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNamee JJ, Gillies MA, Barrett NA, et al. Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial. JAMA 2021; 326:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conrad SA, Zwischenberger JB, Grier LR, et al. Total extracorporeal arteriovenous carbon dioxide removal in acute respiratory failure: a phase I clinical study. Intensive Care Med 2001; 27:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross-Hardt S, Hesselmann F, Arens J, et al. Low-flow assessment of current ECMO/ECCO2R rotary blood pumps and the potential effect on hemocompatibility. Crit Care 2019; 23:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöps M, Groß-Hardt SH, Schmitz-Rode T, et al. Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump. J Transl Med 2021; 19:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Combes A, Tonetti T, Fanelli V, et al. Efficacy and safety of lower versus higher CO2 extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study. Thorax 2019; 74:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ki KK, Passmore MR, Chan CHH, et al. Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. Intensive Care Med Exp 2019; 7:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luyt CE, Bréchot N, Demondion P, et al. Brain injury during venovenous extracorporeal membrane oxygenation. Intensive Care Med 2016; 42:897.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 134496 Version 1.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.elso.org/Portals/0/ELSO%20Guidelines%20General%20All%20ECLS%20Version%201_4.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : https://www.elso.org/Portals/0/ELSO%20Guidelines%20General%20All%20ECLS%20Version%201_4.pdf (Accessed on July 23, 2018).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26116481" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acute Respiratory Distress Syndrome With and Without Extracorporeal Membrane Oxygenation: A Score Matched Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33031151" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Extracorporeal Carbon Dioxide Removal in the Treatment of Status Asthmaticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8404080" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Extracorporeal life support for status asthmaticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9337362" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Emergency extracorporeal life support for patients with near-fatal status asthmaticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092662" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Outcomes using extracorporeal life support for adult respiratory failure due to status asthmaticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27340744" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The use of life-saving extracorporeal membrane oxygenation (ECMO) for pregnant woman with status asthmaticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29559484" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Extracorporeal membrane oxygenation (ECMO) for near-fatal asthma refractory to conventional ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27758969" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Extracorporeal membrane oxygenation support for life-threatening acute severe status asthmaticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23952848" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23952848" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23952848" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23952848" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23952848" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31408142" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30790030" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23306584" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19741487" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34463700" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11511947" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Total extracorporeal arteriovenous carbon dioxide removal in acute respiratory failure: a phase I clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31694688" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Low-flow assessment of current ECMO/ECCO2R rotary blood pumps and the potential effect on hemocompatibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33402176" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31409646" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Efficacy and safety of lower versus higher CO2 extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31432279" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27007107" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Brain injury during venovenous extracorporeal membrane oxygenation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
